DSIP 5mg

Delta Sleep-Inducing Peptide is a naturally occurring nonapeptide first identified for its role in promoting delta (slow-wave) sleep. Since its discovery, DSIP has been studied for its effects on sleep regulation, neurophysiology, and hormonal and endocrine effects.

Sleep Regulation and Circadian Rhythms

DSIP exerts a marked influence on both sleep architecture and circadian rhythms, operating through several distinct mechanisms. Researchers have found that DSIP boosts slow-wave sleep as well as paradoxical (REM) sleep. Interestingly, these effects appear quickly following acute administration, though they don’t persist over time[1]. Beyond its impact on sleep stages, DSIP alters the circadian patterns of both locomotor activity and neurotransmitter levels in the brain[2].

Research studies have demonstrated that DSIP shows promise in laboratory models of phase-shifted sleep patterns and other disruptions to normal circadian cycles[3][4]. The peptide’s effects are not uniform across species; for example, it tends to promote REM sleep in cats but enhances delta wave activity in other animals. DSIP’s reach goes further than just sleep. It also shifts circadian patterns in plasma proteins and cortisol, pointing to a broader role in regulating chronobiological processes[2].

Neuroprotection and Stroke Recovery

DSIP demonstrates impressive neuroprotective effects, especially in models of stroke and neurodegeneration. When researchers administered DSIP intranasally to rats after focal stroke, the animals regained motor function more quickly. These improvements were clear in rotarod test results, even though the actual volume of brain infarction didn’t decrease significantly[5].

DSIP also appears promising as an adjunct to antiepileptic therapies. In studies with lindane-induced seizures, the peptide helped by reducing seizure intensity and extending the time before seizures began[6].

DSIP-like peptides, including KND variants, demonstrate pronounced cardioprotective and neuroprotective effects when administered during reperfusion following ischemic events. The neuroprotective mechanisms involve optimization of excitation/inhibition relationships and modulation of stress-induced neuronal damage[7].

Hormonal and Endocrine Effects

DSIP exerts a strong influence on hormonal regulation, particularly when it comes to growth hormone release and stress response pathways. Researchers have found that DSIP plays a key part in sleep-related growth hormone secretion. In fact, when animals experience sleep deprivation, their endogenous DSIP levels rise, and this increase closely matches elevated plasma growth hormone concentrations.

Research indicates that this peptide engages with opioid-peptidergic systems. Through these interactions, DSIP shapes the circadian rhythms of both neurotransmitter levels and cortisol secretion. Laboratory studies have documented marked effects on withdrawal-like behaviors and pain responses in animal models of dependency, pointing to its involvement in stress and addiction pathways[9].

Research investigations have demonstrated encouraging results in pain management studies. Laboratory findings suggest that DSIP can substantially reduce both pain responses and associated behavioral changes in experimental models of chronic pain.

References

[1] S. Inoué, K. Honda, Y. Komoda, K. Uchizono, R. Ueno, and O. Hayaishi, “Differential sleep-promoting effects of five sleep substances nocturnally infused in unrestrained rats.,” Proceedings of the National Academy of Sciences, Oct. 1984. doi: 10.1073/pnas.81.19.6240. Available: https://doi.org/10.1073/pnas.81.19.6240

[2] G. A. Schoenenberger, “Characterization, Properties and Multivariate Functions of Delta-Sleep-Inducing Peptide (DSIP),” S. Karger AG, 1984. doi: 10.1159/000115711. Available: https://doi.org/10.1159/000115711

[3] D. Schneider-Helmert, E. Hermann, and G. A. Schoenenberger, “[The use of DSIP (delta sleep-inducing peptide) in the correction of phase-shifted insomnia].,” Deutsche Medizinische Wochenschrift, vol. 112 23, pp. 922–5, 1987.

[4] D. Schneider-Helmert and G. A. Schoenenberger, “The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep,” Springer Science and Business Media LLC, Sep. 1981. doi: 10.1007/bf01971753. Available: https://doi.org/10.1007/bf01971753

[5] E. A. Tukhovskaya et al., “Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke,” MDPI AG, Aug. 2021. doi: 10.3390/molecules26175173. Available: https://doi.org/10.3390/molecules26175173

[6] D. Hrncic, Z. Grubac, N. Sutulovic, A. Rasic-Markovic, A. Ademovic, and O. Stanojlovic, “Modulatory effects of delta sleep-inducing peptide in a lindane model of generalized seizures,” National Library of Serbia, 2018. doi: 10.2298/abs180109017h. Available: https://doi.org/10.2298/abs180109017h

[7] E. A. Tukhovskaya et al., “DSIP-Like KND Peptide Reduces Brain Infarction in C57Bl/6 and Reduces Myocardial Infarction in SD Rats When Administered during Reperfusion,” MDPI AG, Apr. 2021. doi: 10.3390/biomedicines9040407. Available: https://doi.org/10.3390/biomedicines9040407

[8] K. S. Iyer, G. A. Marks, A. J. Kastin, and S. M. McCann, “Evidence for a role of delta sleep-inducing peptide in slow-wave sleep and sleep-related growth hormone release in the rat.,” Proceedings of the National Academy of Sciences, May 1988. doi: 10.1073/pnas.85.10.3653. Available: https://doi.org/10.1073/pnas.85.10.3653

[9] W. Larbig, W. D. Gerber, M. Kluck, and G. A. Schoenenberger, “Therapeutic Effects of Delta-Sleep-Inducing Peptide (DSIP) in Patients with Chronic, Pronounced Pain Episodes,” S. Karger AG, 1984. doi: 10.1159/000115716. Available: https://doi.org/10.1159/000115716